An Open-Label Study of Telaprevir Administered Every 12 or 8 Hours in Combination With One of Two Pegylated Interferons and Ribavirin in Treatment-Naive Genotype 1 Chronic Hepatitis C Participants

• Status: Completed
• Trial end date: 2009-08-01

Summary

The purpose of this study is to explore the efficacy, safety, tolerability, pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time), and pharmacokinetic-pharmacodynamic relationships of telaprevir administered in two different doses in combination with two standard therapies commercially available for chronic (lasting a long time) genotype 1 Hepatitis (inflammation of the liver) C virus (HCV) infection.

• Phase: Phase 2

Details

• Lead Sponsor: Tibotec BVBA
• Treatments: Interferon alpha-2; Interferon-alfa-1b; Interferon-alpha; Interferons; Peginterferon alfa-2a; Peginterferon alfa-2b; Pharmaceutical Solutions; Ribavirin